Published in Am J Clin Oncol on August 01, 2009
Therapeutic targeting of SPINK1-positive prostate cancer. Sci Transl Med (2011) 2.83
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 1.32
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer (2011) 1.08
Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 0.99
Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta (2011) 0.89
PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget (2011) 0.89
Cell mates: paracrine and stromal targets for prostate cancer therapy. Nat Rev Urol (2013) 0.87
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol (2011) 0.87
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer. Invest New Drugs (2014) 0.80
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol (2015) 0.80
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget (2015) 0.78
VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. Int J Mol Sci (2015) 0.77
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications. Cancer (2015) 0.76
Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res (2012) 0.75
Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial. Front Pharmacol (2017) 0.75
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol (2009) 2.77
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol (2006) 2.59
Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol (2013) 2.55
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst (2010) 2.12
Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol (2015) 2.12
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology (2014) 2.09
Suicide in lung cancer: who is at risk? Chest (2013) 2.02
Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res (2011) 2.01
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.95
Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol (2004) 1.86
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) (2008) 1.78
Oncology health information quality on the Internet: a multilingual evaluation. Ann Surg Oncol (2011) 1.73
Targeting PI3 kinase/AKT/mTOR signaling in cancer. Crit Rev Oncog (2012) 1.71
Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology (2012) 1.69
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother (2009) 1.66
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood (2008) 1.64
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res (2008) 1.64
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res (2011) 1.56
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
Contemporary management of renal cell carcinoma (RCC) in Victoria: implications for longer term outcomes and costs. BJU Int (2013) 1.50
Uro-oncology multidisciplinary meetings at an Australian tertiary referral centre--impact on clinical decision-making and implications for patient inclusion. BJU Int (2014) 1.49
Breast and prostate cancer: more similar than different. Nat Rev Cancer (2010) 1.48
Differentiation of tumor recurrence from radiation necrosis in high-grade gliomas using 201Tl-SPECT. J Clin Neurosci (2008) 1.47
Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011. Med J Aust (2013) 1.43
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. BJU Int (2013) 1.39
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer (2007) 1.38
Crizotinib and testing for ALK. J Natl Compr Canc Netw (2011) 1.35
Tpl2 kinase regulates T cell interferon-gamma production and host resistance to Toxoplasma gondii. J Exp Med (2008) 1.33
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res (2011) 1.22
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer (2009) 1.21
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 1.19
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res (2006) 1.19
Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res (2008) 1.17
Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2011) 1.16
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res (2009) 1.16
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 1.15
Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther (2003) 1.13
Quality of life and survival in the 2 years after surgery for non small-cell lung cancer. J Clin Oncol (2007) 1.13
What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol (2008) 1.13
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Support Care Cancer (2011) 1.10
The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 1.08
Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun (2003) 1.08
Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate. Eur J Cancer (2010) 1.05
Clinical applications of molecular imaging in sarcoma evaluation. Cancer Imaging (2005) 1.05
Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res (2011) 1.04
Positron emission tomography and molecular imaging of the prostate: an update. BJU Int (2006) 1.03
Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat Rev (2010) 1.03
Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol (2006) 1.03
Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis (2013) 1.03
ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood (2003) 1.03
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica (2005) 1.02
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res (2007) 1.01
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol (2015) 1.01
Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clin Cancer Res (2005) 1.00
Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects. Eur J Immunol (2012) 0.99
Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol (2012) 0.99
Response to erlotinib in a patient with treatment refractory chordoma. Anticancer Drugs (2009) 0.98
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res (2010) 0.98
Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res (2013) 0.98
Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int (2005) 0.97
Left and right ventricular effects of anthracycline and trastuzumab chemotherapy: a prospective study using novel cardiac imaging and biochemical markers. Int J Cardiol (2013) 0.96
A cancer vaccine induces expansion of NY-ESO-1-specific regulatory T cells in patients with advanced melanoma. PLoS One (2012) 0.96
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol (2009) 0.96
A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma. Oral Oncol (2013) 0.96
Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes (2008) 0.95
Inhibitors of mTOR. Oncologist (2010) 0.95
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer (2009) 0.94
Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int (2013) 0.94
A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design. Cancer Res (2009) 0.94
Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol (2005) 0.94
Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J Thorac Oncol (2013) 0.93
Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs (2008) 0.93
A robust human T-cell culture method suitable for monitoring CD8+ and CD4+ T-cell responses from cancer clinical trial samples. J Immunol Methods (2004) 0.93